Netupitant/palonosetron

Netupitant/palonosetron (trade name Akynzeo) is a fixed dose combination drug for prevention of acute and delayed chemotherapy-induced nausea and vomiting[1]. It is marketed and distributed by Helsinn Therapeutics. Netupitant is an NK1 receptor antagonist and palonosetron is a 5-HT3 receptor antagonist.[2]

Netupitant/palonosetron
Combination of
NetupitantNK1 receptor antagonist
Palonosetron5-HT3 receptor antagonist
Clinical data
Trade namesAkynzeo
AHFS/Drugs.comakynzeo
MedlinePlusa614053
License data
Pregnancy
category
  • US: C (Risk not ruled out)
    Routes of
    administration    		Oral
    ATC code
    Legal status
    Legal status
    Identifiers
    KEGG

    Contraindications

    Netupitant/palonosetron is contraindicated during pregnancy.[3]

    Adverse effects

    The most common side effects are headache and constipation. The overall profile of adverse effects is comparable to that of palonosetron (see Palonosetron#Adverse effects); no common adverse effects can be attributed to netupitant.[3]

    Interactions
    Further information: Netupitant § Interactions, and Palonosetron § Interactions

    Pharmacology
    Further information: Netupitant § Pharmacology, and Palonosetron § Pharmacology

    References
    1. "FDA approves Akynzeo for nausea and vomiting associated with cancer chemotherapy". Food and Drug Administration. October 10, 2014.
    2. "Akynzeo: Summary of Product Characteristics" (PDF). European Medicines Agency. Retrieved 12 July 2016.
    3. Haberfeld, H, ed. (2015). Austria-Codex (in German). Vienna: Österreichischer Apothekerverlag. Akynzeo 300 mg / 0,5 mg Hartkapseln.
    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.